BAKER & HOSTETLER LLP for CELGENE CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 34, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HIGGINS | — |
| CHRIS JONES | — |
| TYLER THOMPSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.